公开(公告)号：US20230287123A1

公开(公告)日：2023-09-14

申请号：US17935805

申请日：2022-09-27

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Sandeep P. Inamdar ,  Helen L. Collins ,  Xiang Zhang ,  Hong Xiang

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2827 ,  A61P35/00 ,  A61K2039/505

Abstract: The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient.

公开(公告)号：US20230212299A1

公开(公告)日：2023-07-06

申请号：US18069511

申请日：2022-12-21

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2863 ,  C07K16/2896 ,  A61P35/00 ,  C07K2317/565

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

公开(公告)号：US20220153851A1

公开(公告)日：2022-05-19

申请号：US17513109

申请日：2021-10-28

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  C12N15/11 ,  C12N15/63 ,  A61K39/395 ,  A61K45/06

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

公开(公告)号：US20220031806A1

公开(公告)日：2022-02-03

申请号：US17432640

申请日：2020-02-21

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Susannah D. BARBEE ,  Thomas BRENNAN ,  Barbara SENNINO

IPC: A61K38/17 ,  G01N33/574 ,  A61P35/00

Abstract: The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

公开(公告)号：US11186646B2

公开(公告)日：2021-11-30

申请号：US16737217

申请日：2020-01-08

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/11 ,  C12N15/63 ,  A61K45/06

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

公开(公告)号：US20210340214A1

公开(公告)日：2021-11-04

申请号：US17271792

申请日：2019-08-28

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Sandeep P. INAMDAR ,  Kristen PIERCE ,  Hong XIANG ,  Susannah D. BARBEE

IPC: C07K14/705 ,  A61P35/00 ,  A61K9/00 ,  A61K31/7012 ,  C07K16/18

Abstract: The present disclosure provides methods of administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1) to a subject in need thereof, for example, a cancer patient.

公开(公告)号：US11155615B2

公开(公告)日：2021-10-26

申请号：US15574810

申请日：2016-05-17

Applicant: FIVE PRIME THERAPEUTICS, INC. ,  EUREKA THERAPEUTICS, INC.

Inventor： Brian Wong ,  Emma Masteller ,  Cheng Liu ,  Yiyang Xu ,  Hong Liu ,  Su Yan ,  Jingyi Xiang ,  Pei Wang

IPC: A61K39/00 ,  C07K16/28 ,  A61K51/10 ,  A61K47/68 ,  A61P35/02 ,  A61P35/00 ,  A61K38/05 ,  C07K16/00 ,  G01N33/574 ,  C07K16/30

Abstract: The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

公开(公告)号：US10730949B2

公开(公告)日：2020-08-04

申请号：US16015371

申请日：2018-06-22

Applicant: Five Prime Therapeutics, Inc.

Inventor： Robert Sikorski ,  Julie Hambleton ,  Nilacantan Sankar

IPC: C07K16/28 ,  A61K39/00

Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.

公开(公告)号：US20200237927A1

公开(公告)日：2020-07-30

申请号：US16786158

申请日：2020-02-10

Applicant: Five Prime Therapeutics, Inc.

Inventor： Emma Masteller ,  Thomas Brennan ,  David Bellovin ,  Kevin Baker ,  Brian Wong

IPC: A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

公开(公告)号：US20200182858A1

公开(公告)日：2020-06-11

申请号：US16608911

申请日：2018-04-27

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas BRENNAN ,  Barbara SENNINO ,  Susannah D. BARBEE ,  Ursula JEFFRY

IPC: G01N33/50 ,  G01N15/10

Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.